News
Lille, France – December 5th, 2024 – Alzprotect, a pioneering biopharmaceutical company developing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Professor Christian Bailly to its Board of Directors. Professor Christian Bailly brings to Alzprotect substantial expertise in pharmaceutical research and life sciences, built over more than 30 years of experience. Currently an Associate Professor at the University of Lille and an independent consultant...
Loos March 13Th 2024 ALZPROTECT is thrilled to announce that it has received favorable feedback from both the American (FDA) and European (EMA) authorities regarding the regulatory path for advancing the clinical development of Ezeprogind/AZP2006 for patients with PSP. This significant milestone follows the already very promising results of the phase 2a study in PSP and marks a decisive advancement. It will provide a clear path for the further development of Ezeprogind/AZP2006 within both scient...
Loos, september 21st 2023 World Alzheimer’s day 2023 ALZPROTECT DEVELOPS AN INNOVATIVE TREATMENT AND EXPANDS ITS CLINICAL TRIALS, FOLLOWING VERY POSITIVE RESULT Alzprotect, a biopharmaceutical company based in Lille, is currently testing an innovative drug against a neurodegenerative disease closely related to Alzheimer's disease. The very good results obtained have allowed Alzprotect to extend the clinical trial of this treatment for 6 months, and to prepare a larger scale study. The molecule b...
Lille (France), on 6th March 2023, Alzprotect , a biotechnology company focused on developing treatments for neurodegenerative diseases, announced the appointment of Dr. Olivier Defert as Chief Operating Officer (COO). Dr. Defert brings over 20 years of experience in the biotech and pharmaceutical industries, having held leadership positions in several companies. He is a highly qualified medicinal chemist who has held leadership positions at BioVersys SAS and Tarsier Pharma, among others. He fou...
Lille (France), 16 February 2023 – Alzprotect, the French biopharmaceutical company, announces the extension of its Phase 2a clinical trials of its drug candidate for Progressive Supranuclear Palsy (PSP), a neurodegenerative disease similar to Alzheimer's disease, which severely impacts balance, eye movements, cognition and, in the more advanced stages of the disease, the ability to swallow. The initial C04 study (a randomised, blinded study comparing two doses of AZP2006 to placebo) showed posi...
Lille (France), 20 September 2022 – On the eve of world Alzheimer’s day, Alzprotect, a biopharmaceutical company developing treatments for neurodegenerative diseases, announces the completion of the phase 2a clinical trial evaluating its platform asset, AZP2006 (“EZEPROGIND”) in Progressive Supranuclear Palsy (PSP), a rare neurodegenerative disease, sharing key features with Alzheimer’s disease, and which seriously impacts balance, eye movement, cognition, and in the latter stage of the disease,...
Lille, France – June 1st 2022 – Alzprotect, a French biopharmaceutical company involved in the development of new therapeutic solutions in the neurodegenerative diseases area, today announced it has been awarded a USD $338,000 grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop the first-in-class brain penetrant small molecule targeting Progranulin (PGRN). This grant will further expand Alzprotect’s research efforts to develop AZP2006 (INN Ezeprogind) into a new t...
France, Lille - 5 th April 2022 - Alzprotect, a French biopharmaceutical company specialised in the development of new therapeutic solutions for the treatment of neurodegenerative diseases, in particular Alzheimer's disease, appoints Dr Susanna Del Signore as Chief Medical Officer (CMO). Dr Susanna Del Signore has over 20 years of experience in research and development (R&D) in the pharmaceutical industry, particularly in the field of neurology. She has been a project leader, attaining the posit...
Lille (France), January 20th, 2022 – ALZPROTECT , a biopharmaceutical company developing treatments for neurodegenerative diseases, today announced it has completed patient enrollment for the Company’s phase 2a clinical trial evaluating its platform asset, AZP2006 (“EZEPROGIND”) in Progressive Supranuclear Palsy (PSP), a rare neurodegenerative disorder which seriously impacts walking, balance, eye movement, and in the latter stage of the disease, the ability to swallow. This PSP trial, which is...